文献速递儿科与产科急症消化、代谢与肾脏急症

应激性高血糖与外观病重儿童严重结局的相关性

Association of stress hyperglycemia with severe outcomes in ill-appearing children.
PubMed 文献 · Am J Emerg Med · 2026-08-31
一句话结论外观病重儿童初始血糖≥150 mg/dL者占10.6%,血糖每升高10 mg/dL与严重结局(PICU入住或死亡)独立相关(aOR 1.13),并与气道干预和更长住院时间相关。

该回顾性研究纳入2025年全年经儿科评估三角识别为外观病重的1116名儿童,分析初始毛细血管血糖与挽救生命干预(LSI)、严重结局(PICU入住或死亡)及住院时间的关系。10.6%存在高血糖(≥150 mg/dL),排除糖尿病酮症酸中毒15例后,10.8%入住PICU、0.4%死亡。校正年龄、性别、合并症、高危生命体征和GCS后,血糖每升高10 mg/dL与严重结局独立相关(aOR 1.13,p<0.001)及气道干预相关(aOR 1.10,p=0.001),但与总体LSI无显著关联(p=0.42)。血糖对住院时间的影响随住院时长增加而增大。初始血糖可能作为儿科急诊早期风险评估的有用标志物,但需前瞻性验证。

要点

  • 外观病重儿童中10.6%存在初始高血糖(≥150 mg/dL),糖尿病酮症酸中毒(n=15)被排除。
  • 校正混杂因素后,血糖每升高10 mg/dL与严重结局(PICU入住或死亡)独立相关(aOR 1.13,p<0.001)。
  • 血糖每升高10 mg/dL与气道干预独立相关(aOR 1.10,p=0.001),但与总体LSI无显著关联(p=0.42)。
  • 血糖对严重结局的判别能力有限(AUC 0.654;最佳切点125 mg/dL;敏感度43.3%,特异度80.4%)。
  • 血糖与平均住院时间无关联,但在住院时间第25、50、75百分位处,每10 mg/dL升高分别对应延长0.9、2.5、5.3小时(均p<0.001)。

适用人群与场景

  • 经儿科评估三角(Pediatric Assessment Triangle)识别为外观病重的儿童,就诊于三级儿科急诊(PED)。
  • 排除糖尿病酮症酸中毒患者(n=15)。

诊断标准与关键阈值

  • 高血糖定义为初始毛细血管血糖≥150 mg/dL。
  • 严重结局定义为PICU入住或死亡。
  • 血糖对严重结局的最佳切点为125 mg/dL(AUC 0.654;敏感度43.3%,特异度80.4%)。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 回顾性研究,纳入1116名经儿科评估三角识别为外观病重的儿童,就诊于三级PED,研究期间为2025年1月1日至12月31日。
  • 10.6%存在高血糖(≥150 mg/dL);排除糖尿病酮症酸中毒(n=15)后,10.8%入住PICU,0.4%死亡。
  • 初始毛细血管血糖作为连续变量分析,多变量模型校正年龄、性别、合并症、高危生命体征和GCS评分。
  • 血糖每升高10 mg/dL与严重结局独立相关(aOR 1.13;p<0.001),与气道干预独立相关(aOR 1.10;p=0.001),但与总体LSI无显著关联(p=0.42)。
  • 血糖对严重结局的判别能力:AUC 0.654;最佳切点125 mg/dL;敏感度43.3%,特异度80.4%。
  • 血糖与平均住院时间无关联,但效应随住院时长增加而增大:在第25、50、75百分位处,每10 mg/dL升高分别对应延长0.9、2.5、5.3小时(均p<0.001)。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:单中心、回顾性设计;样本来自单一三级PED;需前瞻性验证。

对床旁实践的改变

  • 在儿科急诊对外观病重儿童测量初始毛细血管血糖,可能有助于早期风险分层,尤其关注气道干预和严重结局风险。
  • 血糖判别严重结局的敏感度仅43.3%,不能单独作为决策依据,需结合其他临床评估。
  • 该研究为回顾性关联分析,不能推出降糖治疗可改善结局;血糖升高应视为风险标志而非治疗靶点。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: We aimed to determine the frequency of stress hyperglycemia (SH) among ill-appearing children, identify clinical correlates of hyperglycemia at presentation, and evaluate the association between glucose levels and life-saving interventions (LSIs), severe outcomes and length of stay (LOS).

METHODS: This retrospective study included ill-appearing children identified by the Pediatric Assessment Triangle who presented to a tertiary PED between January 1 and December 31, 2025. Initial capillary glucose was analyzed as a continuous variable. Multivariable models were adjusted for age, sex, comorbidities, high-risk vital signs, and GCS score. Outcomes included LSIs (airway, hemodynamic, medication, electrical and procedural), severe outcomes (PICU admission or death), and LOS.

RESULTS: Among 1116 children, 10.6% had hyperglycemia (≥150 mg/dL). Patients with diabetic ketoacidosis (n = 15) were excluded. Overall, 10.8% were admitted to the PICU and 0.4% died. Glucose showed modest discrimination for severe outcomes (AUC 0.654; optimal cutoff 125 mg/dL; sensitivity 43.3%, specificity 80.4%). After adjustment, higher glucose levels were independently associated with severe outcomes (aOR 1.13 per 10 mg/dL increase; p < 0.001) and airway intervention (aOR 1.10; p = 0.001), but not with receipt of any LSI overall (p = 0.42). Although glucose was not associated with mean LOS, its effect increased across longer stays, corresponding to increases of 0.9, 2.5, and 5.3 h per 10 mg/dL increase at the 25th, 50th, and 75th percentiles, respectively (all p < 0.001).

CONCLUSIONS: Initial glucose may serve as a useful marker of clinical risk in ill-appearing children. Higher glucose levels were independently associated with airway intervention, severe clinical outcomes and longer hospitalization. These findings suggest that glucose measurement may contribute to early risk assessment in the PED and warrant further prospective validation.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Akcan Yildiz L, Serin O, Bayrak S, et al. Association of stress hyperglycemia with severe outcomes in ill-appearing children. Am J Emerg Med. 2026. PMID: 42705129. doi:10.1016/j.ajem.2026.08.054

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。